FOYJ | Foy-Johnston, Inc. & Extended Watchlist

Foy-Johnston, Inc. FOYJ

FOYJ appeared on our extended watchlist on January 14-15th, when we saw the stock running into resistance at .0009. It was as low as .0006 at the time, and yesterday the stock hit a high of .0015, representing a move of 150%

Now that has broken its previous resistance point .0012, it seems the may be gearing up for blue sky breakout mode, putting us on high alert. We’d like to see the .0012 level hold as support moving forward.

Yesterday following the market close, we saw a PR hit the wires, with a letter to the shareholders. “The company secured its initial exploration project in the country of Cameroon which is located in West Africa, in an area long known for its prolific mineralization. This part of Africa has been extracting gold and other precious minerals for centuries. The Company is currently in the process of acquiring several significant mining concessions in Cameroon as a result of initial exploratory work programs that were conducted over the past several months.”

We always like to monitor a situation carefully following untraded-upon news.

BARCHART.COM is currently giving FOYJ a 96% Overall “Buy” Rating

__

Extended Watchlist:
CIRC, ENTB, XCHC, ORCC, KERX

BMSN, KERX & Extended Watchlist

Bio-Matrix Scientific Group, Inc. BMSN

BMSN has been a main point of focus for us this year. We first began paying close attention to BMSN towards the end of 2012 when it was trading as low as .0003. Yesterday, the stock had another rockstar performance, reaching new highs and cracking through another major resistance point at .0035 (200DMA).

After the initial surge we saw from .0003-.0024, we wanted to see support hold off of .001. Now that we have hit new highs, we are raising the bar and looking for new support to hold  at .0035, or below that, the 20DMA of .0021. If we can see these areas hold as support, we are going to remain bullish on BMSN.

Over the span of our coverage on BMSN, we have been afforded the opportunity at an accumulation of up to 1400% in possible gains from .0003 to yesterday’s high of .0045

Most Recent News:

SAN DIEGO, CA, Jan 24, 2013 (MARKETWIRE via COMTEX) — Regen BioPharma, a wholly owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN), announced today publication in a peer reviewed medical journal the scientific basis for its HemaXellerate(TM) bone marrow failure product. The manuscript is available at http://www.translational-medicine.com/content/pdf/1479-5876-10-231.pdf. The publication is an overview of the Investigational New Drug (IND) application that the company plans to file for initiating clinical trials.

__

Keryx Biopharmaceuticals, Inc. KERX

KERX earned us a spot in the Penny Stock Rumble on Tuesday, racking up another solid day of gains, and hitting a high of 8.79. That brings our total possible profits to a very respectable 154%

We are going to be monitoring the activity on KERX following yesterday’s announcement regarding the comnpany’s planned $55M public offering.

Yesterday’s News:

NEW YORK, Jan. 29, 2013 /PRNewswire via COMTEX/ — Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) today announced that it has commenced a $55 million underwritten public offering of shares of its common stock. In connection with this offering, Keryx expects to grant to the underwriters a 30-day option to purchase additional shares of common stock, equal to up to 15% of the number of shares of common stock sold in the offering. J.P. Morgan is acting as the sole book-running manager in the offering.

__

Extended Watchlist:
SCXN, ITNS, MYRY, SWVI, ONCI, ENTB

XCHC, TSOI, KERX & Extended Watchlist

The X-Change Corporation XCHC

Yesterday, following our alert on XCHC, the stock opened up at .0699, and subsequently hit a high of .079 (+13%) where it ran into some resistance. It then pulled back to .056 before running back to its opening price of .0699 (+25%). We’d call that a solid first day, with total gains of up to 38% presenting themselves.

In press release published yesterday, the company announced its plans to roll out its Phytiva products in S. California. The second announcement of its kind in the last week, we can see that XCHC is rigorously pursuing its quest to expand its recently acquired line.

DALLAS, Jan. 28, 2013 /PRNewswire via COMTEX/ — X-Change Corp. (NASDAQ OTC: XCHC), a U.S. boutique company whose niche is extract-based Cosmeceutical and Nutraceuticals solutions through its Phytiva brand product line, announced today that it has been in discussions with California-based cannabis businesses for plans of a full rollout of Phytiva products to consumers in Southern California.The California legal cannabis market is estimated at $12 -$18 billion in total economic activity, supporting 60,000 to 110,000 jobs and $2.5 to $3.5 billion in legal, taxable wages. The cannabis industry is a much needed windfall for the State of California which is in economic distress. Further, the industry would generate additional income and business taxes for the state. California is one of the leading states for Medical Cannabis since first legalizing in mid 1990’s.

These inquiries came from conservative, well-managed firms that participate in full legal compliance through their dispensary licenses. They have physical locations in place that will allow X-Change Corporation to market its full line of Phytiva products.
__

You may have missed yesterday’s link to our short video presentation of XCHC, so click here and take a look.
__

Recent News:

__

For more information, visit: http://www.phytiva.com
__

Therapeutic Solutions International, Inc. TSOI

A few weeks ago, we noticed TSOI coming off its 52-week low of .01. It was January 14th and 15th when we included it in our extended watchlist, and it was trading as low as .0151. Yesterday the stock managed to close at the high of day of .045, breaching its 20, 50 and 100DMA’s. That move represents a possible gain of 198% from our first mention just two weeks prior.

We would like to see support hold at .04, above the moving averages going forward in order for us to remain bullish on TSOI.

__

Keryx Biopharmaceuticals, Inc. KERX

Speaking of watchlist plays that have made their mark, KERX appeared in our extended watchlist on January 23rd. We’ve since watched it run from a low of 3.46, and we are now observing pre- market trading at 7.03, a gain of 103%

__

Extended Watchlist:
MYRY, IFLM, MILV, PLXT